JDD Buzz Series | Diversity in Melasma Clinical Trials
Underrepresentation of patients with skin of color in clinical trials is an issue in medical research, including in research about dermatological conditions. A study in the January Journal of Drugs in Dermatology looked at the diversity of patients enrolled in melasma clinical trials to determine if there are any disparities in representation.
I interviewed author Jared Jagdeo, MD, MS, associat …
Underrepresentation of patients with skin of color in clinical trials is an issue in medical research, including in research about dermatological conditions. A study in the January Journal of Drugs in Dermatology looked at the diversity of patients enrolled in melasma clinical trials to determine if there are any disparities in representation.
I interviewed author Jared Jagdeo, MD, MS, associat … Continue reading "JDD Buzz Series | Diversity in Melasma Clinical Trials"
A 90-year-old male presents with irregularly shaped macules, 1-4 cm in diameter, that are dark purple with well-defined margins on both forearms. The lesions do not undergo the color changes of a raise and take up to three weeks to resolve. What is the most common cause of this skin condition?
A. Age and photo damage
B. Thick vessel walls
C. Iron deficiency anemia
D. Hereditary hem … 
At the forefront of the evolving treatment landscape for cutaneous squamous cell carcinoma (cSCC), Dr. David M. Miller—a board-certified internist, dermatologist, and medical oncologist at Massachusetts General Hospital—delivered a highly informative lecture on the past, present, and future of immunotherapy for cSCC at ODAC 2025. With his unique expertise across three disciplines, Dr. Miller e … 
The consumer press places a greater emphasis on cosmetic procedures in the winter months, and this year is no exception. Forbes wrote about new skincare treatments to try, including Sofwave, which uses ultrasound to stimulate collagen and elastin. Miria, a new fractionated, non-ablative skin tightening and resurfacing treatment, was featured for its safety in darker skin tones. The article also co … 
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a …